Aveo Pharmaceuticals, Inc. (AVEO) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

Aveo Pharmaceuticals Inc

CIK: 1325879 Ticker: AVEO
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Mar. 15, 2021
Jun. 30, 2020
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2020  
Document Fiscal Year Focus2020  
Document Fiscal Period FocusFY  
Trading SymbolAVEO  
Entity Registrant NameAVEO PHARMACEUTICALS, INC.  
Entity Central Index Key0001325879  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagtrue  
Entity Shell Companyfalse  
Entity Common Stock, Shares Outstanding 27,130,087 
Entity Public Float  $ 105.7
Entity Interactive Data CurrentYes  
Title of 12(g) SecurityCommon Stock, $0.001 par value  
Security Exchange NameNASDAQ  
Entity File Number001-34655  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number04-3581650  
Entity Address, Address Line One30 Winter Street  
Entity Address, City or TownBoston  
Entity Address, State or ProvinceMA  
Entity Address, Postal Zip Code02108  
City Area Code857  
Local Phone Number400-0101  
Document Annual Reporttrue  
Document Transition Reportfalse  
Documents Incorporated by ReferencePortions of our definitive proxy statement for our 2021 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.  

View differences made from one year to another to evaluate Aveo Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aveo Pharmaceuticals Inc.


Assess how Aveo Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aveo Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors




Learn More
Bullish Bearish Neutral
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
Inside Aveo Pharmaceuticals Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income (Loss)
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity (Deficit)
Consolidated Statements Of Stockholders' Equity (Deficit) (Parenthetical)
Assumptions Used In Black Scholes Pricing Model For New Grants (Detail)
Basis Of Presentation
Basis Of Presentation - Additional Information (Detail)
Collaborations And License Agreements
Collaborations And License Agreements (Tables)
Collaborations And License Agreements - Additional Information (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Common Stock
Common Stock - Additional Information (Detail)
Company Net Deferred Tax Assets (Detail)
Employee Benefit Plan
Employee Benefit Plan - Additional Information (Detail)
Future Minimum Payments Under Loans Payable (Detail)
Hercules Loan Facility
Hercules Loan Facility (Tables)
Hercules Loan Facility - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Key Assumptions Used To Value The Warrants (Detail)
Legal Proceedings
Legal Proceedings -Additional Information (Detail)
Organization - Additional Information (Detail)
Other Accrued Liabilities
Other Accrued Liabilities (Detail)
Other Accrued Liabilities (Tables)
Quarterly Results (Unaudited)
Quarterly Results (Unaudited) (Tables)
Reconciliation Of Expected Income Tax Benefit (Detail)
Reconciliation Of Gross Uncertain Tax Positions (Detail)
Significant Accounting Policies
Significant Accounting Policies (Policies)
Significant Accounting Policies (Tables)
Significant Accounting Policies - Additional Information (Detail)
Stock Based Compensation Expense For Equity-Classified Awards (Detail)
Stock Option Activity (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Summary Of Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail)
Summary Of Cash, Cash Equivalents And Marketable Securities (Detail)
Summary Of Changes In Accounts Receivable And Contract Liabilities (Deferred Revenue) (Detail)
Summary Of Computation Of Basic And Diluted Net Loss Per Share (Detail)
Summary Of Fair Value Of Company's Warrant Liability (Detail)
Summary Of Future Minimum Lease Payment (Detail)
Summary Of Outstanding Securities Not Included In Computation Of Diluted Net Loss Per Common Share (Detail)
Summary Of Quarterly Results (Detail)
Summary Of Revenues Earned In Connection With Eusa Agreement Under Asc 606 (Detail)
Summary Of Total Revenues Earned By Partner (Detail)
Ticker: AVEO
CIK: 1325879
Form Type: 10-K Annual Report
Accession Number: 0001564590-21-013607
Submitted to the SEC: Tue Mar 16 2021 4:36:20 PM EST
Accepted by the SEC: Tue Mar 16 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: